How to Help Your Patients Save Money on Vyleesi: A Provider's Guide to Savings Programs

One of the most common reasons patients discontinue or never start Vyleesi (bremelanotide) isn't nausea or discomfort with self-injection — it's cost. Without insurance coverage or cost assistance, a single autoinjector retails for approximately $290, and a month's maximum supply of 8 doses exceeds $2,000. For many patients, this is simply not tenable.

Fortunately, several programs can dramatically reduce what patients pay — but many patients don't know about them and aren't automatically enrolled. As the prescribing provider, you're in the best position to ensure your patients have access to these resources.

This guide covers everything you need to know about Vyleesi savings programs in 2026 and how to build them into your prescribing workflow.

The Vyleesi Cost Landscape in 2026

Understanding the full pricing picture helps you advise patients appropriately:

• Retail cash price (single autoinjector): ~$290
• Retail cash price (4-pack): ~$1,295
• Monthly maximum (8 doses) at retail: Over $2,000
• With BlinkRx Copay Assistance (commercially insured): As little as $0 per fill
• GoodRx / standard discount cards: NOT applicable (specialty pharmacy only)

The clinical reality: most patients in Phase 3 trials used Vyleesi only 2–3 times per month. If a patient uses it 2 times per month and has commercial insurance with the copay program, their actual out-of-pocket cost may be $0–$50. Framing the "worst case" cost for the full 8 doses doesn't reflect typical usage.

Program 1: BlinkRx Copay Assistance (Cosette Pharmaceuticals)

This is the most impactful savings tool available for commercially insured patients, and it should be discussed at every Vyleesi prescribing visit.

Program details:

• Eligible patients pay as little as $0 per fill
• Covers copay, coinsurance, and deductibles
• Applies to up to 2 fills every 30 days
• Requires commercial insurance (not applicable to Medicaid, TRICARE, or Medicare)
• Patient must be 18 or older
• Cannot be applied retroactively — patients must enroll before filling

Enrollment: 1-833-799-5028 or vyleesi.com/getting-started

Practice tip: Many specialty pharmacies ask about copay assistance automatically during the patient intake call. However, patients who have been prescribed Vyleesi and are filling it for the first time may not know to ask. A brief mention at the visit — "When the specialty pharmacy calls you, ask specifically about the manufacturer copay assistance program" — can make a significant difference in adherence.

Program 2: Discounted Cash Price for Uninsured / Underinsured Patients

Patients without insurance or whose commercial insurance doesn't cover Vyleesi can still access a discounted cash price through Cosette's specialty pharmacy support program. The specific discount level varies by patient situation — direct patients to the specialty pharmacy or to 1-833-799-5028 to inquire about their options.

Maximizing Prior Authorization Approval Rates

For commercially insured patients with plans that require prior authorization, the quality of your PA submission directly impacts approval rates — and therefore whether patients can access the insurance benefit that makes Vyleesi affordable.

Best practices for PA submissions:

• Use ICD-10-CM code F52.0 (HSDD). This code is miscoded over one-third of the time, which is the leading cause of avoidable denials.
• Document in the medical record: acquired (patient previously had satisfying desire) and generalized (present regardless of partner/situation) HSDD.
• Include evidence of patient-reported distress or interpersonal difficulty (not just low desire alone).
• Document exclusion of treatable medical, psychiatric, relational, or medication-induced causes.
• Confirm premenopausal status in the PA narrative.
• Consider validated tools (FSFI, DSDS) to provide objective baseline scores.

When Prior Authorization Is Denied

PA denials for Vyleesi are common and often appeal-worthy. Steps to take after a denial:

1. Review the denial reason — most common causes are incomplete documentation or incorrect coding (F52.0 is essential).
2. Submit a formal appeal with supplemental clinical documentation addressing the specific denial reason.
3. Request a peer-to-peer review with the insurer's medical director — many denials reverse at this stage when the clinical picture is presented directly.
4. If the insurer continues to deny, consider requesting a formulary exception for the patient based on medical necessity.

Managing Patients on Government Insurance

For patients on Medicaid, TRICARE, or Medicare who are not eligible for the manufacturer copay program and face limited coverage, options include: requesting state Medicaid coverage exception; discussing the discounted cash price pathway; or evaluating alternatives such as Addyi (flibanserin) or off-label low-dose testosterone, which may have different coverage profiles.

For support identifying specialty pharmacies and navigating access for your patients, medfinder for providers offers tools to help your clinical team locate available pharmacies without the time-consuming phone work.

See also our full provider briefing on Vyleesi availability challenges in 2026 for additional clinical context on the access landscape.